vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and eXp World Holdings, Inc. (EXPI). Click either name above to swap in a different company.

eXp World Holdings, Inc. is the larger business by last-quarter revenue ($1.2B vs $994.2M, roughly 1.2× Charles River Laboratories). eXp World Holdings, Inc. runs the higher net margin — -1.1% vs -27.8%, a 26.7% gap on every dollar of revenue. On growth, eXp World Holdings, Inc. posted the faster year-over-year revenue change (8.5% vs -0.8%). Charles River Laboratories produced more free cash flow last quarter ($58.6M vs $11.9M). Over the past eight quarters, eXp World Holdings, Inc.'s revenue compounded faster (12.4% CAGR vs -0.9%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

eXp World Holdings, Inc. is a global cloud-based real estate services provider. It operates the eXp Realty brokerage network, leverages immersive virtual 3D campus environments to support agent collaboration and operations, serves residential and commercial real estate markets across over 20 countries, and offers complementary services including mortgage, title insurance and professional development resources for real estate practitioners.

CRL vs EXPI — Head-to-Head

Bigger by revenue
EXPI
EXPI
1.2× larger
EXPI
$1.2B
$994.2M
CRL
Growing faster (revenue YoY)
EXPI
EXPI
+9.4% gap
EXPI
8.5%
-0.8%
CRL
Higher net margin
EXPI
EXPI
26.7% more per $
EXPI
-1.1%
-27.8%
CRL
More free cash flow
CRL
CRL
$46.7M more FCF
CRL
$58.6M
$11.9M
EXPI
Faster 2-yr revenue CAGR
EXPI
EXPI
Annualised
EXPI
12.4%
-0.9%
CRL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CRL
CRL
EXPI
EXPI
Revenue
$994.2M
$1.2B
Net Profit
$-276.6M
$-12.9M
Gross Margin
Operating Margin
-28.5%
-1.1%
Net Margin
-27.8%
-1.1%
Revenue YoY
-0.8%
8.5%
Net Profit YoY
-28.9%
-35.7%
EPS (diluted)
$-5.57
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
EXPI
EXPI
Q4 25
$994.2M
$1.2B
Q3 25
$1.0B
$1.3B
Q2 25
$1.0B
$1.3B
Q1 25
$984.2M
$954.9M
Q4 24
$1.0B
$1.1B
Q3 24
$1.0B
$1.2B
Q2 24
$1.0B
$1.3B
Q1 24
$1.0B
$943.1M
Net Profit
CRL
CRL
EXPI
EXPI
Q4 25
$-276.6M
$-12.9M
Q3 25
$54.4M
$3.5M
Q2 25
$52.3M
$-2.3M
Q1 25
$25.5M
$-11.0M
Q4 24
$-214.5M
$-9.5M
Q3 24
$69.7M
$-8.5M
Q2 24
$94.1M
$12.4M
Q1 24
$73.0M
$-15.6M
Gross Margin
CRL
CRL
EXPI
EXPI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
34.6%
99.9%
Q2 24
34.5%
99.9%
Q1 24
34.1%
Operating Margin
CRL
CRL
EXPI
EXPI
Q4 25
-28.5%
-1.1%
Q3 25
13.3%
0.3%
Q2 25
9.7%
-0.2%
Q1 25
7.6%
-1.1%
Q4 24
-16.7%
-1.0%
Q3 24
11.6%
-0.7%
Q2 24
14.8%
1.4%
Q1 24
12.5%
-1.9%
Net Margin
CRL
CRL
EXPI
EXPI
Q4 25
-27.8%
-1.1%
Q3 25
5.4%
0.3%
Q2 25
5.1%
-0.2%
Q1 25
2.6%
-1.2%
Q4 24
-21.4%
-0.9%
Q3 24
6.9%
-0.7%
Q2 24
9.2%
1.0%
Q1 24
7.2%
-1.7%
EPS (diluted)
CRL
CRL
EXPI
EXPI
Q4 25
$-5.57
$-0.08
Q3 25
$1.10
$0.02
Q2 25
$1.06
$-0.01
Q1 25
$0.50
$-0.07
Q4 24
$-4.17
$-0.06
Q3 24
$1.33
$-0.06
Q2 24
$1.74
$0.08
Q1 24
$1.30
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
EXPI
EXPI
Cash + ST InvestmentsLiquidity on hand
$213.8M
$124.2M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$3.2B
$242.8M
Total Assets
$7.1B
$442.5M
Debt / EquityLower = less leverage
0.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
EXPI
EXPI
Q4 25
$213.8M
$124.2M
Q3 25
$207.1M
$112.8M
Q2 25
$182.8M
$94.6M
Q1 25
$229.4M
$115.7M
Q4 24
$194.6M
$113.6M
Q3 24
$210.2M
$130.4M
Q2 24
$179.2M
$108.4M
Q1 24
$327.0M
$109.2M
Total Debt
CRL
CRL
EXPI
EXPI
Q4 25
$2.1B
Q3 25
$2.2B
Q2 25
$2.3B
Q1 25
$2.5B
Q4 24
$2.2B
Q3 24
$2.3B
Q2 24
$2.4B
Q1 24
$2.7B
Stockholders' Equity
CRL
CRL
EXPI
EXPI
Q4 25
$3.2B
$242.8M
Q3 25
$3.4B
$235.3M
Q2 25
$3.4B
$218.4M
Q1 25
$3.2B
$212.0M
Q4 24
$3.5B
$204.9M
Q3 24
$3.8B
$211.1M
Q2 24
$3.7B
$220.3M
Q1 24
$3.6B
$222.4M
Total Assets
CRL
CRL
EXPI
EXPI
Q4 25
$7.1B
$442.5M
Q3 25
$7.5B
$458.7M
Q2 25
$7.6B
$481.2M
Q1 25
$7.6B
$435.8M
Q4 24
$7.5B
$390.7M
Q3 24
$8.0B
$432.6M
Q2 24
$7.9B
$457.4M
Q1 24
$8.2B
$426.7M
Debt / Equity
CRL
CRL
EXPI
EXPI
Q4 25
0.68×
Q3 25
0.64×
Q2 25
0.70×
Q1 25
0.79×
Q4 24
0.65×
Q3 24
0.62×
Q2 24
0.65×
Q1 24
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
EXPI
EXPI
Operating Cash FlowLast quarter
$147.5M
$13.8M
Free Cash FlowOCF − Capex
$58.6M
$11.9M
FCF MarginFCF / Revenue
5.9%
1.0%
Capex IntensityCapex / Revenue
8.9%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$518.5M
$109.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
EXPI
EXPI
Q4 25
$147.5M
$13.8M
Q3 25
$213.8M
$28.9M
Q2 25
$204.6M
$36.1M
Q1 25
$171.7M
$39.8M
Q4 24
$159.4M
$13.7M
Q3 24
$251.8M
$46.0M
Q2 24
$193.5M
$71.1M
Q1 24
$129.9M
$60.7M
Free Cash Flow
CRL
CRL
EXPI
EXPI
Q4 25
$58.6M
$11.9M
Q3 25
$178.2M
$26.6M
Q2 25
$169.3M
$33.3M
Q1 25
$112.4M
$37.3M
Q4 24
$83.7M
$11.6M
Q3 24
$213.1M
$44.4M
Q2 24
$154.0M
$69.7M
Q1 24
$50.7M
$59.3M
FCF Margin
CRL
CRL
EXPI
EXPI
Q4 25
5.9%
1.0%
Q3 25
17.7%
2.0%
Q2 25
16.4%
2.5%
Q1 25
11.4%
3.9%
Q4 24
8.4%
1.1%
Q3 24
21.1%
3.6%
Q2 24
15.0%
5.4%
Q1 24
5.0%
6.3%
Capex Intensity
CRL
CRL
EXPI
EXPI
Q4 25
8.9%
0.2%
Q3 25
3.5%
0.2%
Q2 25
3.4%
0.2%
Q1 25
6.0%
0.3%
Q4 24
7.5%
0.2%
Q3 24
3.8%
0.1%
Q2 24
3.8%
0.1%
Q1 24
7.8%
0.1%
Cash Conversion
CRL
CRL
EXPI
EXPI
Q4 25
Q3 25
3.93×
8.26×
Q2 25
3.91×
Q1 25
6.74×
Q4 24
Q3 24
3.61×
Q2 24
2.06×
5.75×
Q1 24
1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

EXPI
EXPI

North American Realty$1.1B96%
International Realty$42.2M4%

Related Comparisons